Advances in aluminum hydroxide-based adjuvant research and its mechanism

References

• Brewer JM. (How) do aluminum adjuvants work? Immunol Lett 2006; 102:10-15; PMID:16188325; http://dx.doi.org/10.1016/j.imlet.2005.08.002
   PubMed Web of Science ®Google Scholar
• Kuroda E, Coban C, Ishii KJ. Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol 2013; 32:209-20; PMID:23570316; http://dx.doi.org/10.3109/08830185.2013.773326
   PubMed Web of Science ®Google Scholar
• Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974; 59:1317-25; PMID:4606813; http://dx.doi.org/10.1016/0006-291X(74)90458-6
   PubMed Web of Science ®Google Scholar
• Chedid LA, Parant MA, Audibert FM, Riveau GJ, Parant FJ, Lederer E, Choay JP, Lefrancier PL. Biological activity of a new synthetic muramyl peptide adjuvant devoid of pyrogenicity. Infect Immun 1982; 35:417-24; PMID:7035362
   PubMed Web of Science ®Google Scholar
• Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19:2666-72; PMID:11257407; http://dx.doi.org/10.1016/S0264-410X(00)00498-9
   PubMed Web of Science ®Google Scholar
• Negash T, Liman M, Rautenschlein S. Mucosal application of cationic poly(D,L-lactide-co-glycolide) microparticles as carriers of DNA vaccine and adjuvants to protect chickens against infectious bursal disease. Vaccine 2013; 31:3656-62; PMID:23777953; http://dx.doi.org/10.1016/j.vaccine.2013.06.011
   PubMed Web of Science ®Google Scholar
• Wen ZS, Xu YL, Zou XT, Xu ZR. Chitosan nanoparticles act as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Mar Drugs 2011; 9:1038-55; PMID:21747747; http://dx.doi.org/10.3390/md9061038
   PubMed Web of Science ®Google Scholar
• de Titta A, Ballester M, Julier Z, Nembrini C, Jeanbart L, van der Vlies AJ, Swartz MA, Hubbell JA. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc Natl Acad Sci U S A. 2013; 110:19902-07; PMID:24248387; http://dx.doi.org/10.1073/pnas.1313152110
   PubMedGoogle Scholar
• Hussain MJ, Wilkinson A, Bramwell VW, Christensen D, Perrie Y. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants. J Pharm Pharmacol 2014; 66:358-66; PMID:24251796; http://dx.doi.org/10.1111/jphp.12173
   PubMed Web of Science ®Google Scholar
• Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release. 2012; 16:25-37; PMID:22580109; http://dx.doi.org/10.1016/j.jconrel.2012.05.010
   PubMedGoogle Scholar
• Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine 2006; 24 (Suppl 2):S2-26-29; PMID:16823913
   PubMedGoogle Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
   PubMed Web of Science ®Google Scholar
• Warren HS, Chedid LA. Future prospects for vaccine adjuvants. Crit Rev Immunol 1988; 8:83-101; PMID:3276445
   PubMed Web of Science ®Google Scholar
• Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009; 9:287-93; PMID:19247370; http://dx.doi.org/10.1038/nri2510
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354:1343-51; PMID:16571878; http://dx.doi.org/10.1056/NEJMoa055778
   PubMed Web of Science ®Google Scholar
• Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2013; 3:406; PMID:23335921; http://dx.doi.org/10.3389/fimmu.2012.00406
   PubMed Web of Science ®Google Scholar
• Glenny AT, Pope CG, Waddington H, Wallace U. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926; 29:38-45.
   Google Scholar
• Tritto E, Mosca F, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine 2009; 27:3331-4; PMID:19200813; http://dx.doi.org/10.1016/j.vaccine.2009.01.084
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003; 2:197-203; PMID:12899571; http://dx.doi.org/10.1586/14760584.2.2.197
   PubMedGoogle Scholar
• Del Giudice G, Fragapane E, Bugarini R, Hora M, Henriksson T, Palla E, O'hagan D, Donnelly J, Rappuoli R, Podda A. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene. Clin Vaccine Immunol. 2006; 13(9):1010-3; PMID:16960112; http://dx.doi.org/10.1128/CVI.00191-06
   PubMed Web of Science ®Google Scholar
• Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, Montomoli E, Icardi G, Gasparini R, Crovari P. Cross-protection by MF59 -adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26:1525-9; PMID:18294741; http://dx.doi.org/10.1016/j.vaccine.2008.01.019
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Hilbert AK, Bugarini R, Minutello A, Popova O, Toneatto D, Schoendorf I, Borkowski A, Rappuoli R, Podda A. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24:3063-5; PMID:16464520; http://dx.doi.org/10.1016/j.vaccine.2006.01.015
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia T, Durando P, Montomoli E, Capecchi PL, di Giovanni P, Sticchi L, Gentile C, Hilbert A, Brauer V, Tilman S, Podda A. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 2009; 4:e4384; PMID:19197383; http://dx.doi.org/10.1371/journal.pone.0004384
   PubMed Web of Science ®Google Scholar
• Gasparini R, Pozzi T, Montomoli E, Fragapane E, Senatore F, Minutello M, Podda A. Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur J Epidemiol 2001; 17:135-40; PMID:11599686; http://dx.doi.org/10.1023/A:1017919305501
   PubMed Web of Science ®Google Scholar
• Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, Crovari P. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999; 17:99-104; PMID:9987141; http://dx.doi.org/10.1016/S0264-410X(98)00185-6
   PubMed Web of Science ®Google Scholar
• Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines. 2008; 7:1465-73; PMID:19053203; http://dx.doi.org/10.1586/14760584.7.10.1465
   PubMed Web of Science ®Google Scholar
• Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, Leroux-Roels GG, Van Mechelen M. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID:21174144; http://dx.doi.org/10.1007/s10875-010-9490-6
   PubMed Web of Science ®Google Scholar
• Zhao AH, Qiao LY, Jia SZ, Li HK, Wang GZ. Effect of BCG-CpG-DNA as an immunoadjuvant of recombinant HBsAg. Chinese Journal of Biologicals 2007; 20:356-61.
   Google Scholar
• Li S, Luo C, Cao J. Clinical therapeutic effect of vaccae combined with Hepatitis B vaccine and persantine in the treatment of HBsAg carrier. China Medicine 2007; 2:338-9.
   Google Scholar
• Ma J, Wang H, Zheng X, Xue X, Wang B, Wu H, Zhang K, Fan S, Wang T, Li N, Zhao Y, Gao Y, Yang S, Xia X. CpG/Poly (I:C) mixed adjuvant priming enhances the immunogenicity of a DNA vaccine against eastern equine encephalitis virus in mice. Int Immunopharmacol 2014; 19:74-80; PMID:24440303; http://dx.doi.org/10.1016/j.intimp.2014.01.002
   PubMed Web of Science ®Google Scholar
• Quinn KM, Yamamoto A, Costa A, Darrah PA, Lindsay RW, Hegde ST, Johnson TR, Flynn BJ, Loré K, Seder RA. Coadministration of polyinosinic:polycytidylic acid and immunostimulatory complexes modifies antigen processing in dendritic cell subsets and enhances HIV gag-specific T cell immunity. J Immunol 2013; 191:5085-96; PMID:24089189; http://dx.doi.org/10.4049/jimmunol.1301730
   PubMed Web of Science ®Google Scholar
• Hem, SL, HogenEsch H. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev Vaccines 2007; 6, 685-98; PMID:17931150; http://dx.doi.org/10.1586/14760584.6.5.685
   PubMed Web of Science ®Google Scholar
• Flarend RE, Hem SL, White JL, Elmore D, Suckow MA, Rudy AC, Dandashliti EA. In vivo absorption of aluminum-containing vaccine adjuvants using 26Al. Vaccine 1997; 15:1314-8; PMID:9302736; http://dx.doi.org/10.1016/S0264-410X(97)00041-8
   PubMed Web of Science ®Google Scholar
• Shirodkar S, Hutchinson RL, Perry DL, White JL, Hem SL. Aluminum compounds used as adjuvants in vaccines. Pharm Res 1990; 7:1282-8; PMID:2095567; http://dx.doi.org/10.1023/A:1015994006859
   PubMed Web of Science ®Google Scholar
• al-Shakhshir R, Regnier F, White JL, Hem SL. Effect of protein adsorption on the surface charge characteristics of aluminum-containing adjuvants. Vaccine 1994; 12:472-4; PMID:8023556; http://dx.doi.org/10.1016/0264-410X(94)90127-9
   PubMed Web of Science ®Google Scholar
• Rinella JV, Jr, White JL, Hem SL. Treatment of aluminum hydroxide adjuvant to optimize the adsorption of basic proteins. Vaccine 1996; 14:298-300; PMID:8744556; http://dx.doi.org/10.1016/0264-410X(95)00194-6
   PubMedGoogle Scholar
• Pinto VV, Salanti A, Joergensen LM, Dahlbäck M, Resende M, Ditlev SB, Agger EM, Arnot DE, Theander TG, Nielsen MA. The effect of adjuvants on the immune response induced by a DBL4ϵ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria. Vaccine 2012; 30:572-9; PMID:22122859; http://dx.doi.org/10.1016/j.vaccine.2011.11.068
   PubMedGoogle Scholar
• Pelka K, Latz E. Getting closer to the dirty little secret. Immunity 2011; 34:455-8; PMID:21511178; http://dx.doi.org/10.1016/j.immuni.2011.04.003
   PubMedGoogle Scholar
• Harrison WT. Some observations on the use of alum precipitated diphtheria toxoid. Am J Public Health Nations Health 1935; 25:298-300; PMID:18014174; http://dx.doi.org/10.2105/AJPH.25.3.298
   PubMedGoogle Scholar
• Johnston CT, Wang SL, Hem SL. Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci 2002; 91:1702-06; PMID:12115832; http://dx.doi.org/10.1002/jps.10166
   PubMed Web of Science ®Google Scholar
• Shi Y, HogenEsch H, Regnier FE, Hem SL. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001; 19:1747-52; PMID:11166900; http://dx.doi.org/10.1016/S0264-410X(00)00394-7
   PubMed Web of Science ®Google Scholar
• Matheis W, Zott A, Schwanig M. The role of the adsorption process for production and control combined adsorbed vaccines. Vaccine 2001; 20:67-73; PMID:11567747; http://dx.doi.org/10.1016/S0264-410X(01)00317-6
   PubMedGoogle Scholar
• Holt LB. Developments in dipheria prophylaxis. Heinemann Medical Books, London 1950. pp1-181.
   Google Scholar
• Hutchison S, Benson RA, Gibson VB, Pollock AH, Garside P, Brewer JM. Antigen depot is not required for alum adjuvanticity. FASEB J 2011; 26:1272-9; PMID:22106367; http://dx.doi.org/10.1096/fj.11-184556
   PubMedGoogle Scholar
• Gupta RK, Chang AC, Griffin P, Rivera R, Siber GR. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 1996; 14:1412-6; PMID:8994315; http://dx.doi.org/10.1016/S0264-410X(96)00073-4
   PubMed Web of Science ®Google Scholar
• Shi Y, HogenEsch H, Hem SL. Change in the degree of adsorption of proteins by aluminum-containing adjuvants following exposure to interstitial fluid: freshly prepared and aged model vaccines. Vaccine 2001; 20:80-85; PMID:11567749; http://dx.doi.org/10.1016/S0264-410X(01)00313-9
   PubMedGoogle Scholar
• Weissburg RP, Berman PW, Cleland JL, Eastman D, Farina F, Frie S, Lim A, Mordenti J, Nguyen TT, Peterson MR. Characterization of the MN gp120 HIV-1 vaccine: antigen binding to alum. Pharm Res 1995; 12:1439-46; PMID:8584477; http://dx.doi.org/10.1023/A:1016266916893
   PubMed Web of Science ®Google Scholar
• Heimlich JM, Regnier FE, White JL, Hem SL. The in vitro displacement of adsorbed model antigens from aluminum-containing adjuvants by interstitial proteins. Vaccine 1999; 17:2873-81; PMID:10438058; http://dx.doi.org/10.1016/S0264-410X(99)00126-7
   PubMed Web of Science ®Google Scholar
• Mannhalter JW, Neychev HO, Zlabinger GJ, Ahmad R, Eibl MM. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminum hydroxide: effect on antigen uptake and antigen presentation. Clin Exp Immunol. 1985; 61:143-51; PMID:3876178
   PubMed Web of Science ®Google Scholar
• Iyer S, HogenEsch H, Hem SL. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. Vaccine 2003; 21:1219-23; PMID:12559801; http://dx.doi.org/10.1016/S0264-410X(02)00556-X
   PubMed Web of Science ®Google Scholar
• Rimaniol AC, Gras G, Verdier F, Capel F, Grigoriev VB, Porcheray F, Sauzeat E, Fournier JG, Clayette P, Siegrist CA, et al. Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. Vaccine 2004; 22:3127-35; PMID:15297065; http://dx.doi.org/10.1016/j.vaccine.2004.01.061
   PubMed Web of Science ®Google Scholar
• Sun B, Ji Z, Liao YP, Wang M, Wang X, Dong J, Chang CH, Li R, Zhang H, Nel AE, et al. Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. ACS Nano 2013; 7:10834-49; PMID:24261790; http://dx.doi.org/10.1021/nn404211j
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 2007; 178:5271-6; PMID:17404311; http://dx.doi.org/10.4049/jimmunol.178.8.5271
   PubMed Web of Science ®Google Scholar
• Kool M, Pétrilli V, De Smedt T, Rolaz A, Hammad H, van Nimwegen M, Bergen IM, Castillo R, Lambrecht BN, Tschopp J. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 Inflammasome. J Immunol 2008; 181:3755-9; PMID:18768827; http://dx.doi.org/10.4049/jimmunol.181.6.3755
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singhd M, Kazzaz J, et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responsesto influenza vaccine in mice. Vaccine 2008; 26:552-61; PMID:18162266; http://dx.doi.org/10.1016/j.vaccine.2007.11.054
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminum adjuvants. Nature 2008; 453:1122-6; PMID:18496530; http://dx.doi.org/10.1038/nature06939
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009; 21:23-29; PMID:19246182; http://dx.doi.org/10.1016/j.coi.2009.01.004
   PubMed Web of Science ®Google Scholar
• Kool M, Soullié T, van Nimwegen M, Willart MA, Muskens F, Jung S, Hoogsteden HC, Hammad H, Lambrecht BN. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008; 205:869-82; PMID:18362170; http://dx.doi.org/10.1084/jem.20071087
   PubMed Web of Science ®Google Scholar
• Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, Aritake K, Urade Y, Morimoto Y. Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity 2011; 34:514-26; PMID:21497116; http://dx.doi.org/10.1016/j.immuni.2011.03.019
   PubMed Web of Science ®Google Scholar
• Kool M, Willart MAM, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, Rogers N, Osorio F, Reis e Souza C, Hammad H, et al. An unexpected role for uric acid as an inducer of T helper 2 cell immunity to inhaled antigens and inflammatory mediator of allergic asthma. Immunity 2011; 34:527-40; PMID:21474346; http://dx.doi.org/10.1016/j.immuni.2011.03.015
   PubMedGoogle Scholar
• Exley C, Siesjö P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010; 31:103-09; PMID:20153253; http://dx.doi.org/10.1016/j.it.2009.12.009
   PubMed Web of Science ®Google Scholar
• Wang XY, Yao X, Wan YM, Wang B, Xu JQ, Wen YM. Responses to multiple injections with alum alone compared to injections with alum adsorbed to proteins in mice. Immunol Lett 2013; 149:88-92; PMID:23183095; http://dx.doi.org/10.1016/j.imlet.2012.11.005
   PubMed Web of Science ®Google Scholar
• Jordan MB, Mills DM, Kappler J, Marrack P, Cambier JC. Promotion of B cell immune responses via an alum-induced myeloid cell population. Science 2004; 304:1808-10; PMID:15205534; http://dx.doi.org/10.1126/science.1089926
   PubMed Web of Science ®Google Scholar
• Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, Lekeux P, Coban C, Akira S, Ishii KJ, et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011; 17:996-1002; PMID:21765404; http://dx.doi.org/10.1038/nm.2403
   PubMed Web of Science ®Google Scholar
• Gavin AL, Hoebe K, Duong B, Ota T, Martin C, Beutler B, Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 2006; 314:1936-38; PMID:17185603; http://dx.doi.org/10.1126/science.1135299
   PubMed Web of Science ®Google Scholar
• Flach TL, Ng G, Hari A, Desrosiers MD, Zhang P, Ward SM, Seamone ME, Vilaysane A, Mucsi AD, Fong Y, et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011; 17:479-87; PMID:21399646; http://dx.doi.org/10.1038/nm.2306
   PubMed Web of Science ®Google Scholar
• Ramanathan VD, Badenoch-Jones P, Turk JL. Complement activationby aluminum and zirconium compounds. Immunology 1979; 37:881-8; PMID:500133
   PubMed Web of Science ®Google Scholar
• Seeber SJ, White JL, Hem SL. Predicting the adsorption of proteins by aluminum-containing adjuvants. Vaccine 1991; 9:201-3; PMID:2042392; http://dx.doi.org/10.1016/0264-410X(91)90154-X
   PubMed Web of Science ®Google Scholar
• Morefield GL, Jiang D, Romero-Mendez IZ, Geahlen RL, Hogenesch H, Hem SL. Effect of phosphorylation of ovalbumin on adsorption by aluminum containing adjuvants and elution upon exposure to interstitial fluid. Vaccine 2005; 23:1502-6; PMID:15670886; http://dx.doi.org/10.1016/j.vaccine.2004.08.048
   PubMed Web of Science ®Google Scholar
• Liu JC, Feldkamp JR, White JL, Hem SL. Adsorption of phosphate by aluminum hydroxycarbonate. J Pharm Sci 1984; 73:1355-8; PMID:6502480; http://dx.doi.org/10.1002/jps.2600731007
   PubMed Web of Science ®Google Scholar
• Bleam WF, Pfeffer PE, Goldberg S, Taylor RW, Dudley RA. 31P solid-state nuclear magnetic resonance study of phosphate adsorption at the boehmite/aqueous solution interface. Langmuir 1991; 7:1702-1712; http://dx.doi.org/10.1021/la00056a023
   Web of Science ®Google Scholar
• Hingston FJ, Atkinson RJ, Posner AM, Quirk JP. Specific adsorption of anions. Nature (London) 1967; 215:1459-61; http://dx.doi.org/10.1038/2151459a0
   Web of Science ®Google Scholar
• Gupta RK , Rost BE , Relyveld E, Siber GR. Adjuvant Properties of Aluminum and Calcium Compounds. IN MF Powell, MJ Newman and JR Burdman (Eds.). Vaccine design: the subunit and adjuvant approach. New York: Plenum Press 1995; 229-s>48
   Google Scholar
• Jendrek S, Little SF, Hem S, Mitra G, Giardina S. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants. Vaccine 2003; 21:3011-8; PMID:12798645; http://dx.doi.org/10.1016/S0264-410X(03)00109-9
   PubMed Web of Science ®Google Scholar
• Chang M, Shi Y, Nail SL, HogenEsch H, Adams SB, White JL, Hem SL. Degree of antigen adsorption in the vaccine or interstitial fluid and its effect on the antibody response in rabbits. Vaccine 2001; 19:2884-9; PMID:11282199; http://dx.doi.org/10.1016/S0264-410X(00)00559-4
   PubMed Web of Science ®Google Scholar
• Hansen B, Sokolovska A, HogenEsch H, Hem SL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine 2007; 25:6618-24; PMID:17681647; http://dx.doi.org/10.1016/j.vaccine.2007.06.049
   PubMed Web of Science ®Google Scholar
• Tian JN, Ye XZ, Zhang N, Zhang MX, Xian YL, Liu XF, Zhang JH, Li YM. Relation between phosphate and immunopotentiation of recombinant HEV-aluminum hydroxide adjuvant vaccines. Immunological Journal 2010; 26:120-3.
   Google Scholar
• Clausi A, Cummiskey J, Merkley S, Carpenter JF, Braun LJ, Randolph TW. Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine. J Pharm Sci 2008; 97:5252-62; PMID:18398901; http://dx.doi.org/10.1002/jps.21390
   PubMedGoogle Scholar
• Huai LP, Liu H, Zhang N, Sun JF, Wang YY, Wei H. The effect of the different size of aluminum hydroxide particles on optimum immunity of diphtheria toxoid. Prog in Microbiol Immunol 2011; 39:15-16.
   Google Scholar
• Ye L, Liu DY, Zhao T, Liang W, Zou JG, Zhang L, Zeng XM, Su L. Comparison on the effect of recombinant hepatitis B vaccines adjuvanted with aluminum hydroxide from the two different prescriptions. Prog in Microbiol Immunol 1999; 27:51-53.
   Google Scholar
• Gherardi RK, Coquet M, Cherin P, Belec L, Moretto P, Dreyfus PA, Pellissier JF, Chariot P, Authier FJ. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminum hydroxide in muscle. Brain 2001; 124:1821-31; PMID:11522584; http://dx.doi.org/10.1093/brain/124.9.1821
   PubMed Web of Science ®Google Scholar
• Zhang Y, Luo DY, Liu JS, Xing L, Zhang SL, He R, Zhou LL, Lin XJ, Wang XL. Research on the production technics of split avian enfluenza vaccine for human. Med J Chin PLA 2006; 31:1209-20.
   Google Scholar
• Li LF, Yang HJ. Overview on development of immune adjuvant. Prog in Microbiol Immunol 1997; 25:57-61.
   Google Scholar
• Gherardi RK, Coquet M, Chérin P, Authier FJ, Laforêt P, Bélec L, Figarella-Branger D, Mussini JM, Pellissier JF, Fardeau M. Macrophagic myofasciitis: an emerging entity. Lancet 1998; 352:347-52; PMID:9717921; http://dx.doi.org/10.1016/S0140-6736(98)02326-5
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 2003; 23:699-712; PMID:14753387; http://dx.doi.org/10.1016/S0889-8561(03)00095-X
   PubMed Web of Science ®Google Scholar
• Shingde M, Hughes J, Boadle R, Wills EJ, Pamphlett R. Macrophagic myofasciitis associated with vaccine-derived aluminum. Med J Aust 2005; 183:145-6; PMID:16053418
   PubMed Web of Science ®Google Scholar
• Israeli E, Agmon-Levin N, Blank M, Shoenfeld Y. Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease. Clin Rev Allergy Immunol 2011; 41:163-8. ; PMID:20882368; http://dx.doi.org/10.1007/s12016-010-8212-4
   PubMed Web of Science ®Google Scholar
• Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminum in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypotheses 2009; 72:135-9; PMID:19004564; http://dx.doi.org/10.1016/j.mehy.2008.09.040
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen J, Chen SH, Cao J, Xiong W, Chen EX, Xue HG, Li XG, Xiang MJ. Hypersusceptibility of aluminum hydroxide adjuvant. Chinese Journal of Biologicals 2011; 24:1171-3.
   Google Scholar
• Levy R, Shohat L, Solomon B. Specificity of an anti-aluminum monoclonal antibody toward free and protein-bound aluminum. J Inorg Biochem 1998; 69:159-63; PMID:9629674; http://dx.doi.org/10.1016/S0162-0134(97)10013-7
   PubMed Web of Science ®Google Scholar
• McLean AA, Shaw R Jr. Hepatitis B vaccine. Ann Intern Med 1982; 97:451; PMID:7114644; http://dx.doi.org/10.7326/0003-4819-97-3-451_1
   PubMedGoogle Scholar
• Chen D, Tyagi A, Carpenter J, Perkins S, Sylvester D, Guy M, Kristensen DD, Braun LJ. Characterization of the freeze sensitivity of a hepatitis B vaccine. Human Vaccines 2009; 5:26-32; PMID:18971625; http://dx.doi.org/10.4161/hv.5.1.6494
   PubMed Web of Science ®Google Scholar
• Boros CA, Hanlon M, Gold MS, Roberton DM. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines. Vaccine 2001; 19:3537-42; PMID:11348721; http://dx.doi.org/10.1016/S0264-410X(01)00063-9
   PubMedGoogle Scholar
• Vogel FR and SL Hem. Immunologic Adjuvants In S Plotkin, W. Orenstein, and P. Offit (Eds.), Vaccines, Fifth Edition.2008: 59-71.
   Google Scholar
• Braun LJ, Tyagi A, Perkins S, Carpenter J, Sylvester D, Guy M, Kristensen D, Chen D. Development of a freeze-stable formulation for vaccines containing aluminum salt adjuvants. Vaccine 2009; 27:72-79; PMID:18973782; http://dx.doi.org/10.1016/j.vaccine.2008.10.027
   PubMed Web of Science ®Google Scholar
• Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. Freezing temperatures in the vaccine cold chain: a systematic literature review. Vaccine 2007; 25:3980-6; PMID:17382434; http://dx.doi.org/10.1016/j.vaccine.2007.02.052
   PubMed Web of Science ®Google Scholar
• Theeten H, Van Damme P, Hoppenbrouwers K, Vandermeulen C, Leback E, Sokal EM, Wolter J, Schuerman L. Effects of lowering the aluminum content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents. Vaccine 2005; 23:1515-21; PMID:15670888; http://dx.doi.org/10.1016/j.vaccine.2004.08.002
   PubMed Web of Science ®Google Scholar
• Norimatsu M, Ogikubo Y, Aoki A, Takahashi T, Watanabe G, Taya K, Sasamoto S, Tsuchiya M, Tamura Y. Effects of aluminum adjuvant on systemic reactions of lipopolysaccharides in swine. Vaccine 1995; 13:1325-9; PMID:8585288; http://dx.doi.org/10.1016/0264-410X(95)00023-T
   PubMed Web of Science ®Google Scholar
• Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: a systematic review. Vaccine 2012; 30:6971-9; PMID:23041122; http://dx.doi.org/10.1016/j.vaccine.2012.09.059
   PubMed Web of Science ®Google Scholar
• Berthold I, Pombo ML, Wagner L, Arciniega JL. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants. Vaccine 2005; 23:1993-9; PMID:15734073; http://dx.doi.org/10.1016/j.vaccine.2004.10.014
   PubMed Web of Science ®Google Scholar
• Hu ZY, Zhu FC, He P, Liu SL, Zhang R, Fang X, Zhai XJ, Qiu SH, Liang ZL, Wang H, et al. Study on the kinesis of cellular immunity in adults vaccinated with recombinant hepatitis B vaccine. Zhonghua Liu Xing Bing Xue Za Zhi 2007; 28:326-30; PMID:17850695
   PubMedGoogle Scholar
• He P, Hu ZY, Liang ZL, Li HM, Zhuang H. Comparison of cytokine levels induced by different types of HBV vaccines in mice.China J Biologicals 2011; 24:1075-1078.
   Google Scholar
• Wang YP, Li MY, Gao F, Shao J, Mao QY, Yao X, Cheng G, You S, Liang ZL. Effect of aluminum hydroxide adjuvant on cellular immune response induced with inactivated enterovirus 71 vaccine in mice. Chin J Biologicals 2012; 25:939-42.
   Google Scholar
• Diminsky D, Schirmbeck R, Reimann J, Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997; 15:637-47; PMID:9178464; http://dx.doi.org/10.1016/S0264-410X(96)00239-3
   PubMed Web of Science ®Google Scholar
• Hu ZY, He P, Fang X, Qiu SH, Liang ZL, Li HM, Zhuang H. Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines. Zhonghua Liu Xing Bing Xue Za Zhi 2008; 29:810-4; PMID:19103120
   PubMedGoogle Scholar
• Callahan PM, Shorter AL, Hem SL. The importance of surface charge in the optimization of antigen-adjuvant interactions. Pharm Res 1991; 8:851-8; PMID:1924135; http://dx.doi.org/10.1023/A:1015843210358
   PubMedGoogle Scholar
• Kreuter J, Liehl E. Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. J Pharm Sci 1981; 70:367-71; PMID:7229943; http://dx.doi.org/10.1002/jps.2600700406
   PubMed Web of Science ®Google Scholar
• He P, Lǚ FL, Chen Y, Li YC, He FC. Immune effect of HBsAg adsorbed by nanoparticulate alum adjuvant. Chemical Journal of Chinese Universities 2005; 26:886-8.
   Web of Science ®Google Scholar
• He P, Lǚ FL, Chen Y, Zuo GW, Li YC, He FC. Synthesis of nanoparticulate alum adjuvant and its application to the HBsAg and rabies virus. Immunological Journal 2006; 22:90-93.
   Google Scholar
• Tang C, Yue H, Lu FL, Jing B. Quickening humour immune response to avian influenza virus induced by nanoparticulate alum adjuvant in chichen. Journal of Southwenst University for Nationalities-Natural Science Edition 2006; 32:956-8.
   Google Scholar
• Tang C, Huang X, Yang FL, Li MY, Fan GC, Yue H. Adjuvant effect of aluminum hydroxide nanoparticles on Newcastle diseases antigen in chichens. Chinese Veterinary Science 2008; 38:1060-4.
   Google Scholar
• Liang CJ, Wang J, Li XM, Lu FL, Zhang Y, Chen J. The comparative study of the physical and chemical attributes of nanoparticulated aluminum hydroxide adjuvant before and after autoclaving. China Biotechnol 2007; 27:81-85.
   Google Scholar
• Shvedova AA, Kisin ER, Mercer R, Murray AR, Johnson VJ, Potapovich AI, Tyurina YY, Gorelik O, Arepalli S, Schwegler-Berry D, et al. Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice. Am J Physiol Lung Cell Mol Physiol 2005; 289:698-708.
   PubMed Web of Science ®Google Scholar
• Hussain SM, Hess KL, Gearhart JM, Geiss KT, Schlager JJ. In vitro toxicity of nanoparticles in BRL 3A rat liver cells. Toxicol In Vitro 2005; 19:975-83; PMID:16125895
   PubMed Web of Science ®Google Scholar
• Tsuji JS, Maynard AD, Howard PC, James JT, Lam CW, Warheit DB, Santamaria AB. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Sci 2006; 89:42-50; PMID:16177233
   PubMed Web of Science ®Google Scholar
• Wang JX, Li YF, Zhou GQ, Li B, Jiao F, Chen CY, Gao YX, Zhao YL, Chai ZF. Influence of intranasal instilled titanium dioxide nanoparticles on monoaminergic meurotransmitters of female mice at different exposure time. Chin J Prev Med 2007; 41:91-95.
   Google Scholar
• Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008; 8:235-47; PMID:18194079
   PubMed Web of Science ®Google Scholar
• Mbow ML, De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr Opin Immunol 2010; 22:411-6; PMID:20466528
   PubMed Web of Science ®Google Scholar
• Segal L, Wilby OK, Willoughby CR, Veenstra S, Deschamps M. Evaluation of the intramuscular administration of CervarixTM vaccine on fertility, pre- and post-natal development in rats. Reprod Toxicol 2011; 31:111-20; PMID:20851759
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM, Morel S, Lockman L, Giannini SL, Bisteau M, Carlsen H, Kielland A, Vosters O, Vanderheyde N, Schiavetti F, et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009; 183:6186-97; PMID:19864596
   PubMed Web of Science ®Google Scholar
• Zhao AH, Li FX, Zhang J, Wang GZ. Effect of BCG-CpG-DNA on the immunogenicity of HBsAg. Prog in Microbiol Immunol 2008; 36:10-14.
   Google Scholar